---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-135767"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:57:45.674384+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026

## Summary
- Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.
- Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.
- Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.
- Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets.

## SEC filing metadata
- accession: 0001193125-26-135767
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/0001193125-26-135767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/d63145d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-135767
- JSON: https://secwatch.observer/filing/0001193125-26-135767.json
- Plain text: https://secwatch.observer/filing/0001193125-26-135767.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the year ended December 31, 2025 results: net income $(69,375) thousand, EPS $(4.71).
  - Period: the year ended December 31, 2025
  - Net income: $(69,375) thousand
  - EPS: $(4.71)
  - Result: reported results
  source text: Interest income 2,715 1,314 Other expense, net (396 ) (190 ) Total other income, net 2,319 1,124 Net loss before taxes (68,338 ) (35,478 ) Income tax expense 1,037 — Net loss $ (69,375 ) $ (35,478 ) Per share information: Net loss per share - basic and diluted $ (4.71 ) $ (12.17 ) Weighted average share, and pre-funded warrants outstanding, basic and diluted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/0001193125-26-135767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.